カタログ製品コード : C-E1805h
ELISA kit for Kininogen-1
24T | ¥89,900 | (¥3,746/T) (税別) |
48T | ¥103,100 | (¥2,148/T) (税別) |
96T | ¥122,800 | (¥1,279/T) (税別) |
標準納期 : 2週間 |
カタログ製品コード : C-E1805h
ELISA kit for Kininogen-1
24T | ¥89,900 | (¥3,746/T) (税別) |
48T | ¥103,100 | (¥2,148/T) (税別) |
96T | ¥122,800 | (¥1,279/T) (税別) |
標準納期 : 2週間 |
メーカー名 | 遺伝子名 | 種交差性 | 測定範囲 | サンプル量 | 適用サンプル | ドキュメント |
---|---|---|---|---|---|---|
EIAab | KNG1 | Human | 1.56-100 ng/mL | 100 μl | 血清、血漿、尿、組織ホモジネート、細胞培養上清等 |
■保存方法 :
一時保存の場合
TMB:4℃
試薬類:バイアルに記載の温度
長期保存の場合
-20℃
■測定原理 :
The microtiter plate provided in this kit has been pre-coated with an antibody specific to . Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB substrate solution is added to each well. Only those wells that contain , biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of in the samples is then determined by comparing the O.D. of the samples to the standard curve.
■構成内容 :
Reagent | Quantity |
Assay plate | 1 |
Standard | 2 |
Sample Diluent | 1 × 20ml |
Assay Diluent A | 1 × 10ml |
Assay Diluent B | 1 × 10ml |
Detection Reagent A | 1 × 120μl |
Detection Reagent B | 1 × 120μl |
Wash Buffer(25 x concentrate) | 1 × 30ml |
Substrate | 1 × 10ml |
Stop Solution | 1 × 10ml |
Plate sealer for 96 wells | 5 |
Instruction | 1 |
■キーワード :
Homo sapiens,Human,Kininogen-1,Alpha-2-thiol proteinase inhibitor,Fitzgerald factor,High molecular weight kininogen,HMWK,Williams-Fitzgerald-Flaujeac factor,KNG1,BDK,KNG
■ターゲット情報 :
(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.